RQ-01 / Red Queen Therap - LARVOL DELTA

Phase 1 Study of Intranasal Fusion Inhibitor RQ-01 for the Treatment of Covid-19 (ASM Microbe 2024) - "RQ-01 is a novel fusion inhibitor that was safe and well-tolerated when administered intranasally to subjects with mild COVID-19."

P1 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects (clinicaltrials.gov) - P1 | N=66 | Completed | Sponsor: Red Queen Therapeutics, Inc. | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects (clinicaltrials.gov) - P1 | N=66 | Active, not recruiting | Sponsor: Red Queen Therapeutics, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects (clinicaltrials.gov) - P1 | N=66 | Recruiting | Sponsor: Red Queen Therapeutics, Inc.

New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases